Jill Beraud has been appointed to Revance Therapeutics Board of Directors. She will also chair a newly formed Revance Brand Strategy Committee focused on establishing the company’s innovative neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in the minds of consumers.
Beraud, who has more than 25 years experience building luxury brands, is currently co-founder and CEO of Sh’nnong Beverage Company. Prior to that, she served as CEO of IPPOLITA, a fine jewelry company with distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom and other national retailers. Previously she held the role of executive vice president, global retail and e-commerce, for Tiffany & Co., where she was responsible for all global retail, operations, e-commerce, digital and omni-channel consumer experience. Beraud has also worked with brands, such as Living Proof, Levi Strauss, Starbucks/Lipton Joint Ventures and Victoria’s Secret, and served as global chief marketing officer at PepsiCo. In 2013, she was named to Fast Company’s “Most Creative People in Business.”
“We are delighted to welcome Jill Beraud to our Board at this pivotal time in our company’s trajectory. She arrives at an ideal moment as we establish a rarity among biotech companies—a Brand Strategy Committee dedicated to understanding and embracing the consumer mindset,” said Dan Browne, president and CEO of Revance. “Jill’s board experience with Levi Strauss and track record of launching high-growth businesses and powerhouse consumer brands at firms such as Pepsi, Victoria’s Secret and Tiffany & Co., will be invaluable as we approach commercialization. We look forward to working with her to unlock the true promise of what our long-acting neuromodulator, DAXI, can deliver.”
Image: Jill Beraud
